Can Canopy Growth stay ahead of pot rival Aurora Cannabis?

Investors are ready for a battle royale as the marijuana stocks release earnings.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article was originally published on Fool.com

Marijuana stocks have captured the imagination of high-growth investors, who hope that major companies in the industry will be able to take early command of the budding cannabis market and become household names across the globe. Among the top companies in the field, Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) have emerged as true contenders with their early-mover status, and with the backing of Constellation Brands, Canopy seems like a natural favorite to become the real leader of the marijuana market.

Canopy Growth expects to release its fiscal second-quarter financial report on Wednesday, Nov. 14, and investors will be looking closely at the company to see whether it can keep up the pace in a fast-growing market. Indeed, with Aurora Cannabis having reported sales for the September quarter that were higher than what Canopy brought in three months early, Canopy is in a position in which it’s having to play catch-up — at least temporarily — to stay ahead of Aurora Cannabis from a revenue standpoint.

Tweed-branded products lined up in boxes and bottles on a wood mantle in front of a wood-paneled wall.

IMAGE SOURCE: CANOPY GROWTH.

Stats on Canopy Growth’s fiscal second-quarter earnings

EPS Estimate

(CA$0.08)

Last Quarter’s EPS

(CA$0.23)

Revenue Estimate

CA$75.3 million

Change From Last Quarter’s Revenue

190%

DATA SOURCE: S&P GLOBAL MARKET INTELLIGENCE.

A big boom for Canopy Growth?

Canopy Growth investors are looking for an extremely strong performance from the cannabis producer for the third quarter. Revenue is expected nearly to triple, and although Canopy isn’t likely to become profitable as long as it has so much growth potential in which to invest any available financial resources, its bottom line is seen showing considerable improvement even compared to just three months ago as sales ramp up.

That level of sales growth is important from a competitive standpoint, because peers in the industry have also seen big leaps in revenue. For instance, Aurora Cannabis said Monday that its fiscal first-quarter revenue jumped 260% to 29.7 million Canadian dollars, with cannabis-related revenue climbing at a 236% pace year over year. Operationally, Aurora managed to see dramatic improvements in key metrics, including production volume that almost quintupled, sales volume by weight that tripled, and active registered patient counts that were up 250% from year-earlier levels.

Seeking to be the industry leader

Yet Canopy Growth has already demonstrated a solid track record of delivering big results. In its fiscal first-quarter report three months ago, Canopy reported a 63% rise in revenue, with strength in several essential measures of success. Selling prices per gram improved by nearly CA$1 to CA$8.94, and the company boasted more than 85,000 patients in the medical cannabis sector. The company’s key Spectrum Cannabis soft-gel product continued to gain traction, with an operational network spanning 11 companies.

Canopy is pursuing growth in several directions. The company’s wholly owned subsidiary Canopy Health Innovations is looking at clinical trials of cannabis for treating insomnia, and it expects further research to continue. The Canopy Animal Health unit will do similar work for potential veterinary treatments.

The most important thing for Canopy to concentrate on right now, however, is the opportunity to serve the new recreational cannabis market in Canada. In preparation for the mid-October legalization of marijuana, Canopy had already sought to maximize the amount of cannabis it would deliver to provincial and territorial governments for the post-legalization rollout, and co-CEO Bruce Linton noted back in August that it had already secured commitments to provide an estimated 36% of total supply, giving it “by far the deepest channel into the Canadian recreational cannabis market.”

What to watch for

Indeed, Linton sees the company as the key innovator in the marijuana space in Canada for the foreseeable future. As the co-CEO put it:

To drive our brand down to main street Canada and capture retail margin, we successfully invested in securing Tweed cannabis store licenses in Newfoundland and Labrador, Manitoba, and Saskatchewan, and we expect to leverage these successes in Alberta as well as in the anticipated private retail framework in Ontario. Canopy is developing the leading private cannabis retail channel in Canada.

Of course, those numbers won’t even show up in Canopy’s fiscal second-quarter results, because the quarter ended on Sept. 30 prior to the rollout of Canadian recreational marijuana. What will appear, though, is a full reckoning of all the supply agreements Canopy was able to secure, along with an early picture of how post-legalization sales have gone. Those numbers should go a long way toward telling whether the company is making the most of its opportunities.

Don’t stop looking at Canopy Growth

With a flood of marijuana earnings reports coming out this week, there’ll be a lot of competition for your attention. But with such a strong track record so far, Canopy Growth is a marijuana stock that deserves a close look, not just for its own sake but also as an indicator of how the entire cannabis industry is performing.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool US recommends Constellation Brands. The Motley Fool has a disclosure policy.

 

More on Investing Articles

UK money in a Jar on a background
Investing Articles

With a 10.1% yield, should I buy this FTSE 250 income stock?

Our writer looks at an income stock that’s kept its dividend unchanged for five years. But is it high enough…

Read more »

Investing Articles

Up 23% in a month, can this FTSE 100 stock continue to soar?

Airtel Africa's recently been the FTSE 100’s top-performing stock. With huge opportunities for growth ahead, is it set to continue?

Read more »

Investing Articles

£20,000 in savings? Here’s how an investor could use it to target an eventual £980 of passive income each month

Our writer demonstrates how an investor could aim to earn close to £1,000 each month in passive income from a…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

£10,000 invested in the S&P 500 at the start of 2025 is now worth…

Since the start of the year, the S&P 500's underperformed the FTSE 100. And Stephen Wright thinks investing in the…

Read more »

Investing Articles

Is this a turning point for the Diageo share price?

The Diageo share price is at an eight-year low. Is this FTSE 100 favourite simply too cheap to ignore? Roland…

Read more »

Investing Articles

As the FTSE 100 hits record highs, should I sell my shares and buy an index fund?

Our writer’s portfolio lagged the FTSE 100 last year, but he’s not giving up on stock-picking and highlights a recent…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

£10,000 invested in Lloyds shares 6 months ago is now worth…

Lloyds shares have performed well over 12 months but have broadly disappointed investors over the long run. Dr James Fox…

Read more »

Investing Articles

£20,000 in savings? Here’s how investors can aim for a £4,000 monthly second income

Millions of investors use the Stocks and Shares ISA as a vehicle to build wealth and generate a second income.…

Read more »